Cargando…

Dietary Supplement Use and Interactions with Tamoxifen and Aromatase Inhibitors in Breast Cancer Survivors Enrolled in Lifestyle Interventions

The use of dietary supplements is common in the general population and even more prevalent among cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research specifies that dietary supplements should not be used for cancer prevention. Several dietary supplements have poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrigan, Maura, McGowan, Courtney, Hood, Annette, Ferrucci, Leah M., Nguyen, ThaiHien, Cartmel, Brenda, Li, Fang-Yong, Irwin, Melinda L., Sanft, Tara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621720/ https://www.ncbi.nlm.nih.gov/pubmed/34835986 http://dx.doi.org/10.3390/nu13113730

Ejemplares similares

Changes in diet quality in a randomized weight loss trial in breast cancer survivors: the lifestyle, exercise, and nutrition (LEAN) study
por: Anderson, Chelsea, et al.
Publicado: (2016)

Randomized trial of weight loss on circulating ghrelin levels among breast cancer survivors
por: Puklin, Leah, et al.
Publicado: (2021)

Effect of the Lifestyle, Exercise, and Nutrition (LEAN) Study on Long-Term Weight Loss Maintenance in Women with Breast Cancer
por: Lisevick, Alexa, et al.
Publicado: (2021)

Randomized Trial Evaluating a Self-Guided Lifestyle Intervention Delivered via Evidence-Based Materials versus a Waitlist Group on Changes in Body Weight, Diet Quality, Physical Activity, and Quality of Life among Breast Cancer Survivors
por: Puklin, Leah S., et al.
Publicado: (2023)

Effect of healthy diet and exercise on chemotherapy completion rate in women with breast cancer: The Lifestyle, Exercise and Nutrition Early after Diagnosis (LEANer) study: Study protocol for a randomized clinical trial
por: Sanft, Tara, et al.
Publicado: (2021)

Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study
por: Sanft, Tara, et al.
Publicado: (2023)

Diet and physical activity interventions in Black and Latina women with breast cancer: A scoping review
por: Pichardo, Margaret S., et al.
Publicado: (2023)

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
por: Dieli-Conwright, Christina M., et al.
Publicado: (2022)

Post-diagnosis weight trajectories and mortality among women with breast cancer
por: Puklin, Leah S., et al.
Publicado: (2023)

Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors
por: Meyerhardt, Jeffrey A, et al.
Publicado: (2019)

Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial
por: Cao, Anlan, et al.
Publicado: (2023)

Precautions for Patients Taking Tamoxifen or Aromatase Inhibitors
por: Heery, Mary
Publicado: (2023)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
por: Sawada, Tomoya, et al.
Publicado: (2023)

Effect of Exercise on Sarcopenia among Cancer Survivors: A Systematic Review
por: Cao, Anlan, et al.
Publicado: (2022)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Delivery of Cancer Survivorship Education to Community Healthcare Professionals
por: Pariser, Ashley C., et al.
Publicado: (2022)

Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer
por: Cartmel, Brenda, et al.
Publicado: (2023)

Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
por: Cuzick, J, et al.
Publicado: (2006)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort
por: Blondon, Marc, et al.
Publicado: (2022)

Stick or switch? Audit of the use of switch therapy from tamoxifen to an aromatase inhibitor in breast cancer
por: Weeraman, S, et al.
Publicado: (2010)

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
por: Huiart, L, et al.
Publicado: (2011)

Persistence with tamoxifen and aromatase inhibitors in Germany: a retrospective cohort study with 284,383 patients
por: Gremke, Niklas, et al.
Publicado: (2022)

Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
por: Bromley, Susan E., et al.
Publicado: (2019)

Correction to: Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK
por: Bromley, Susan E., et al.
Publicado: (2019)

Lifetime history of indoor tanning in young people: a retrospective assessment of initiation, persistence, and correlates
por: Lostritto, Karen, et al.
Publicado: (2012)

Incidence of Comorbidities in Women with Breast Cancer Treated with Tamoxifen or an Aromatase Inhibitor: An Australian Population-Based Cohort Study
por: Ng, Huah Shin, et al.
Publicado: (2018)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

Host phenotype characteristics and MC1R in relation to early-onset basal cell carcinoma
por: Ferrucci, Leah M., et al.
Publicado: (2011)

Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data
por: Choi, Sung Hyouk, et al.
Publicado: (2020)

Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors
por: Wang, Tzu-Fei, et al.
Publicado: (2022)

What influences aromatase inhibitor continuation intention among breast cancer survivors?
por: Seo, Young Kyung, et al.
Publicado: (2021)

Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time
por: Shaaban, Adnan, et al.
Publicado: (2023)

Tamoxifen in breast cancer survivors with COVID 19: stop or go?
por: Karacin, Cengiz, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

Cognitive Effects and Depression Associated With Taxane-Based Chemotherapy in Breast Cancer Survivors: A Meta-Analysis
por: Ibrahim, Eiman Y., et al.
Publicado: (2021)

Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
por: Pineda-Moncusí, Marta, et al.
Publicado: (2020)

Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors
por: Romero, Sally A.D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_036fu7u4g7dnhrk64fqd8m7a1s